The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 of 40 cited sources checked · 4 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Partly supportedcites [284] Galiè, 2016, Eur Heart J sourceExperimental — accuracy not yet measured
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > INTRODUCTION:
What the sources say
- Partly supportedcites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > RISK FACTORS TO BE CONSIDERED: > Functional Status and Frailty:
What the sources say
- Partly supportedcites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc sourceExperimental — accuracy not yet measured
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
- Supportedcites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
The Discussion states that frailty is associated with both waitlist and post-transplant mortality. It also says further work is needed to identify valid frailty measures before using them in organ allocation; the available passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CYSTIC FIBROSIS
What the sources say
- Supportedcites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
The Discussion reports improved survival but an approximately 10% annual probability of death once FEV1 falls below 30% predicted. The Conclusions add that some patients die soon after reaching that threshold, while others live for many years. (LLM, conf=0.92)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > PSYCHOSOCIAL RISK FACTORS: > Nicotine:
What the sources say
- Partly supportedcites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis sourceExperimental — accuracy not yet measured
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > NON-CYSTIC FIBROSIS BRONCHIECTASIS
What the sources say
- Could not verifycites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > LYMPHANGIOLEIOMYOMATOSIS (LAM)
What the sources say
- Partly supportedcites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
- Supportedcites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
The Introduction describes LAM as rare and says it accounted for about 1% of heart or lung transplantation indications in an international survey. The Discussion reports that the Japanese LAM recipients had more favorable post-transplant survival than patients transplanted for other indications. The printed citing sentence does not make a claim about bilateral transplantation. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- Not checked — no full text of the sourcecites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- Not checked — no full text of the sourcecites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Not checked — no full text of the sourcecites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- Could not verifycites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Partly supportedcites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
- Partly supportedcites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
- Partly supportedcites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- Partly supportedcites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ sourceExperimental — accuracy not yet measured
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
- Not matchedcites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Citations
Cites
Items 201–349 of 349
The impact of pre-transplant allosensitization on outcomes after lung transplantation
Bosanquet, J. P., Witt, C. A., Bemiss, B. C., Byers, D. E., Yusen, R. D., Patterson, A. G., Kreisel, D., Mohanakumar, T., Trulock, E. P., & Hachem, R. R. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.06.003 · Cited by 45 · cited 1×
“However, some centers describe successful lung transplantation despite positive cross match.(62,63) Cut-off levels for organ acceptance and the optimal methods for detection of functional donor specific antibodies have not been determined.”
BackgroundPre-transplant weight loss and clinical outcomes after lung transplantation
Clausen, E. S., Frankel, C., Palmer, S. M., Snyder, L. D., & Smith, P. J. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.07.015 · Cited by 45 · cited 1×
“These patients should be encouraged to lose weight as the magnitude of pre-transplant weight loss is directly correlated with improvements in post-transplant survival for candidates who are not underweight.(43,44) While low BMI has been associated with increased mortality, Cystic fibrosis (CF) recipients with BMI <17…”
BackgroundSelf-citationKhawar, M. U., Yazdani, D., Zhu, Z., Jandarov, R., Dilling, D. F., & Gupta, N. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.06.015 · Cited by 45
Extremes of age decrease survival in adults after lung transplant
Lehr, C. J., Blackstone, E. H., McCurry, K. R., Thuita, L., Tsuang, W. M., & Valapour, M. (2020) · Chest · doi:10.1016/j.chest.2019.06.042 · Cited by 45 · cited 1×
“7 The age of lung transplant recipients has increased over the past decade.”
BackgroundSelf-citationABO-Incompatible Lung Transplantation in an Infant
Grasemann, H., de Perrot, M. E., Bendiak, G. N., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03861.x · Cited by 44
Self-citationLung cancer: a rare indication for, but frequent complication after lung transplantation
Raemdonck, D. V., Vos, R., Yserbyt, J., Decaluwe, H., Leyn, P. D., & Verleden, G. M. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.05 · Cited by 44
Brouckaert, J., Verleden, S. E., Verbelen, T., Coosemans, W., Decaluwé, H., Leyn, P. D., Depypere, L., Nafteux, P. R., Veer, H. G. L. V., Meyns, B. P., et al. (2019) · Transplant International · doi:10.1111/tri.13409 · Cited by 44
Outcomes for lung transplantation for lung cancer in the United Network for Organ Sharing Registry
Ahmad, U., Wang, Z., Bryant, A. S., Kim, A. W., Kukreja, J., Mason, D. P., Bermudez, C. A., Detterbeck, F. C., & Boffa, D. J. (2012) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.04.069 · Cited by 43 · cited 2×
“321,322,330 Modifying the surgical approach as suggested to reduce aerogenous contamination of donor lungs at the time of implantation may mitigate the risk of relapse post-transplant.”
BackgroundAmbulatory ECMO as a bridge to lung transplant in a previously well pediatric patient with ARDS
Turner, D. A., Rehder, K. J., Bonadonna, D., Gray, A., Lin, S., Zaas, D., & Cheifetz, I. M. (2014) · Pediatrics · doi:10.1542/peds.2013-3435 · Cited by 43
Paraskeva, M. A., Edwards, L. B., Levvey, B. J., Stehlik, J., Goldfarb, S., Yusen, R. D., Westall, G. P., & Snell, G. I. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.02.017 · Cited by 43 · cited 1×
“127,131 Growth : In the pre-transplant period optimizing growth and nutritional status in children is important, not only as preparation for the operation, but also because growth may be attenuated by medications post-transplant Extracorporeal Membrane Oxygenation (ECMO) : In the past, ECMO was…”
BackgroundImpact of high-priority allocation on lung and heart-lung transplantation for pulmonary hypertension
Savale, L., Le Pavec, J., Mercier, O., Mussot, S., Jaïs, X., Fabre, D., O’Connell, C., Montani, D., Stephan, F., Sitbon, O., et al. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.02.034 · Cited by 42
Underweight Patients With Cystic Fibrosis Have Acceptable Survival Following Lung Transplantation
Ramos, K. J., Kapnadak, S. G., Bradford, M. C., Somayaji, R., Morrell, E. D., Pilewski, J. M., Lease, E. D., Mulligan, M. S., Aitken, M. L., Gries, C. J., et al. (2020) · Chest · doi:10.1016/j.chest.2019.11.043 · Cited by 42 · cited 2×
“45 Of note, the mechanisms underlying adverse effects of high or low BMI on transplant outcomes are not well understood.”
BackgroundSelf-citationComprehensive outcomes after lung retransplantation: A single‐center review
Halloran, K., Aversa, M., Tinckam, K., Martinu, T., Binnie, M., Chaparro, C., Chow, C., Waddell, T., McRae, K., Pierre, A., et al. (2018) · Clinical Transplantation · doi:10.1111/ctr.13281 · Cited by 42 · cited 1×
“140,146,150,151 In the pre-transplant evaluation of such patients, particular emphasis should be focused on understanding the possible reasons for the graft failure, such as alloimmunization, poor adherence, GER, or repeated infections.”
BackgroundSelf-citationThe impact of donor and recipient age: older lung transplant recipients do not require younger lungs
Hall, D. J., Jeng, E. I., Gregg, J. A., Pelaez, A., Emtiazjoo, A. M., Chandrashekaran, S., Pipkin, M., Beaver, T. M., & Machuca, T. N. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.09.066 · Cited by 42 · cited 1×
“11,12 In summary, while older age is increasingly Table 2 Risk factors for poor post-transplant outcomes Risk factors can change over time and may not be a contraindication for referral, but when present at the time of listing or while listed for lung transplantation may increase risk for poor…”
BackgroundFriedman, D. Z. P., Cervera, C., Halloran, K., Tyrrell, G., & Doucette, K. (2020) · Transplant Infectious Disease · doi:10.1111/tid.13229 · Cited by 42 · cited 1×
“64,65 66-69 Thus, patients with M. abscessus should be managed at centers with expertise and protocols for managing this infection.”
BackgroundSharp, C., Adamali, H. I., & Millar, A. B. (2017) · ERJ Open Research · doi:10.1183/23120541.00096-2016 · Cited by 41
Hayes, D., Higgins, R. S., Black, S. M., Wehr, A. M., Lehman, A. M., Kirkby, S., & Whitson, B. A. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.09.004 · Cited by 41
Psychosocial predictors of medication adherence in pediatric heart and lung organ transplantation
Killian, M. (2017) · Pediatric Transplantation · doi:10.1111/petr.12899 · Cited by 41
Sher, Y., Mooney, J., Dhillon, G., Lee, R., & Maldonado, J. R. (2017) · Clinical Transplantation · doi:10.1111/ctr.12966 · Cited by 41
Banga, A., Mohanka, M., Mullins, J., Bollineni, S., Kaza, V., Tanriover, B., & Torres, F. (2017) · Clinical Transplantation · doi:10.1111/ctr.13106 · Cited by 41 · cited 1×
“Outcomes are consistently worse for patients who develop renal failure requiring renal replacement therapy.(18) In select candidates with concomitant CKD, consideration may be given for possible simultaneous lung-kidney transplant or staged lung-kidney transplant (see multiorgan transplantation section below).”
BackgroundLung transplantation as a therapeutic option in acute respiratory distress syndrome
Chang, Y., Lee, S. O., Shim, T. S., Choi, S. H., Kim, H. R., Kim, Y.-H., Kim, D. K., Do, K.-H., Choi, I.-C., Hong, S.-B., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002004 · Cited by 41
Meyers, B. F., Yusen, R. D., Guthrie, T. J., et al. (2001) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2001.115239 · Cited by 40
Bavaria, J. E., Pochettino, A., Kotloff, R. M., Rosengard, B. R., Wahl, P. M., Roberts, J., Palevsky, H. I., & Kaiser, L. R. (1998) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(98)70437-4 · Cited by 39 · cited 1×
“…has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of transplant.”
BackgroundSelf-citationKhadawardi, H. A., & Mura, M. (2016) · Respirology · doi:10.1111/resp.12945 · Cited by 39 · cited 1×
“197 204-209 In patients with concurrent emphysema, a decline in FVC is a less reliable parameter to detect progression of fibrosis, and other markers such as progression of disease on CT scan or DLCO, or development of secondary pulmonary hypertension, may be more useful.”
BackgroundLung Retransplantation for Chronic Rejection: A Single-Center Experience
Roy, S. B., Panchanathan, R. S., Walia, R., Varsch, K. E., Kang, P. T., Huang, J. L., Hashimi, A. S., Mohanakumar, T., Bremner, R. M., & Smith, M. A. (2017) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2017.07.025 · Cited by 39
Clinical outcomes of lung transplantation in the presence of donor-specific antibodies
Courtwright, A. M., Cao, S., Wood, I., Mallidi, H. R., Kawasawa, J., Moniodis, A., Ng, J., El-Chemaly, S., & Goldberg, H. J. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201812-869oc · Cited by 39
Changes in neurocognitive functioning following lung transplantation
Hoffman, B. M., Blumenthal, J. A., Carney, R. C., O’Hayer, C. V. F., Freedland, K., Smith, P. J., Babyak, M. A., Davis, R. D., Mathew, J. P., Martinu, T., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04072.x · Cited by 38
Self-citationGas exchange and exercise capacity affect neurocognitive performance in patients with lung disease
Parekh, P. I., Blumenthal, J. A., Babyak, M. A., LaCaille, R., Rowe, S., Dancel, L., Carney, R. M., Davis, R. D., & Palmer, S. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000160479.99765.18 · Cited by 38
Psychiatric morbidity in patients undergoing heart, heart and lung, or lung transplantation
Trumper, A., & Appleby, L. (2001) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(00)00214-2 · Cited by 38
Evaluation of solid organ transplant candidates for coronary artery disease
Manoushagian, S., & Meshkov, A. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12915 · Cited by 38 · cited 1×
“Thus, evaluation for CAD should remain a part of transplant candidacy assessment.(22) Consultation with a cardiologist familiar with lung transplant candidate selection should be considered for the development of protocols for pre-transplant assessment and management.”
BackgroundMarijuana use in transplantation: a call for clarity
Levi, M. E., Montague, B. T., Thurstone, C., Kumar, D., Huprikar, S. S., Kotton, C. N., & the Executive Committee of the Infectious Diseases Community of Practice of the American Society of Transplantation (2019) · Clinical Transplantation · doi:10.1111/ctr.13456 · Cited by 38
Interpretation of workplace tests for cannabinoids
Kulig, K. (2017) · Journal of Medical Toxicology · doi:10.1007/s13181-016-0587-z · Cited by 37 · cited 1×
“86,111 115-119 Orally consumed cannabis should only be used prior to transplant if recommended by a medical provider, and if approved by the lung transplant team.”
BackgroundNash, E. F., Volling, C., Gutierrez, C. A., Tullis, E., Coonar, A., McRae, K., Keshavjee, S., Singer, L. G., Durie, P. R., & Chaparro, C. (2012) · Clinical Transplantation · doi:10.1111/j.1399-0012.2010.01395.x · Cited by 37 · cited 1×
“269 Data are limited on the impact of CF-associated liver disease on lung transplant outcomes; however, in cases of overt portal hypertension or synthetic dysfunction, combined lung-liver transplant has had comparable outcomes to lung transplant alone, particularly over the long-term.”
BackgroundLung Transplantation for lymphangioleiomyomatosis in Japan
Ando, K., Okada, Y., Akiba, M., Kondo, T., Kawamura, T., Okumura, M., Chen, F., Date, H., Shiraishi, T., Iwasaki, A., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0146749 · Cited by 37
Mycobacterium abscessus Complex – a Particular Challenge in the Setting of Lung Transplantation
Smibert, O., Snell, G. I., Bills, H., Westall, G. P., & Morrissey, C. O. (2016) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2016.1138856 · Cited by 37 · cited 1×
“64,65 66-69 Thus, patients with M. abscessus should be managed at centers with expertise and protocols for managing this infection.”
BackgroundHofmann, P., Benden, C., Kohler, M., & Schuurmans, M. M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.16 · Cited by 37 · cited 1×
“86,111 115-119 Orally consumed cannabis should only be used prior to transplant if recommended by a medical provider, and if approved by the lung transplant team.”
BackgroundLung Transplantation After Lung Volume Reduction Surgery
Shigemura, N., Gilbert, S., Bhama, J. K., Crespo, M. M., Zaldonis, D. B., Pilewski, J. M., & Bermudez, C. A. (2013) · Transplantation · doi:10.1097/tp.0b013e31829853ac · Cited by 36 · cited 1×
“185,188,189 188-190”
Ameye, H., Ruttens, D., Benvéniste, O., et al. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.09.163 · Cited by 36 · cited 1×
“31 Esophageal Dysfunction / Gastrointestinal Dysmotil-ity/ Gastroesophageal reflux (GER) : Post-transplant GER is variably associated with increased risk of acute rejection, pulmonary infection and earlier development of chronic lung allograft dysfunction (CLAD).”
BackgroundEffects of Smoking on Solid Organ Transplantation Outcomes
ANIS, K. H., Weinrauch, L. A., & D’Elia, J. A. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.11.005 · Cited by 36
Retransplantation Outcomes at a Large Lung Transplantation Program
Ren, D., Kaleekal, T. S., Graviss, E. A., Nguyen, D. T., Sinha, N., Goodarzi, A., Agboli, I., Suarez, E. E., Loebe, M. M., Scheinin, S. A., et al. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000844 · Cited by 36
Hayes, D., Higgins, R. S., Kirkby, S., McCoy, K. S., Wehr, A. M., Lehman, A. M., & Whitson, B. A. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.12.004 · Cited by 35
Lehr, C. J., Skeans, M., Dasenbrook, E., Fink, A., Fernandez, G., Faro, A., & Valapour, M. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0252oc · Cited by 35 · cited 1×
“…mycobacteria ( M. abscessus in particular) have been shown to increase the rate of lung function decline or death without transplant in advanced CF. 245,247,254,258,262 Implications of B. cenoce-pacia, M. abscessus , or L. prolificans are described above (infectious disease risk factors).”
BackgroundSelf-citationHayes, D., Black, S. M., Tobias, J. D., Mansour, H. M., & Whitson, B. A. (2016) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2015.1043425 · Cited by 34
Outcomes of lung volume reduction surgery followed by lung transplantation: a matched cohort study
Burns, K. E. A., Keenan, R. J., Grgurich, W. F., Manzetti, J. D., & Zenati, M. A. (2002) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(02)03499-9 · Cited by 34 · cited 1×
“185,188,189 188-190”
Şenbaklavacı, Ö. (2002) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/s1010-7940(02)00354-8 · Cited by 34
Parize, P., Boussaud, V., Poinsignon, V., Sitterlé, E., Botterel, F., Lefeuvre, S., Guillemain, R., Dannaoui, É., & Billaud, E. M. (2017) · Transplant Infectious Disease · doi:10.1111/tid.12738 · Cited by 34 · cited 1×
“70,71 Burkholderia cepacia complex : Burkholderia cepacia complex includes several genotypically distinct bacteria, the most common of which are B. cenocepaci a and B.multi-vorans.”
BackgroundPerez, A. A., Singer, J. P., Schwartz, B. S., Chin‐Hong, P., Shah, R. J., Kleinhenz, M. E., Gao, Y., Venado, A., Leard, L. E., Golden, J. A., et al. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13084 · Cited by 34
Self-citationChaikriangkrai, K., Jyothula, S., Jhun, H. Y., Estep, J., Loebe, M., Scheinin, S., & Torre-Amione, G. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.08.009 · Cited by 33 · cited 1×
“25 Peripheral Vascular Disease (PVD) : PVD is considered a risk factor for limiting rehabilitation post-transplant and poses a risk of ischemic limb complications with peri-operative use of ECLS.”
BackgroundOutcomes and Long-term Survival After Pulmonary Retransplantation: A Single-Center Experience
Wallinder, A., Danielsson, C., Magnusson, J., Riise, G. C., & Dellgren, G. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.04.028 · Cited by 33
Self-citationBackhus, L. M., Sargent, J. E., Cheng, A. M., Zeliadt, S. B., Wood, D. E., & Mulligan, M. S. (2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.01.045 · Cited by 32 · cited 1×
“185,188,189 188-190”
Specific aspects of children and adolescents undergoing lung transplantation
Benden, C. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283564fba · Cited by 32
Saunders, P. T., Toshner, R., & Maher, T. M. (2018) · doi:10.1201/9781315113807-52 · Cited by 32
The burden of sinus disease in cystic fibrosis lung transplant recipients
Morlacchi, L. C., Greer, M., Tudorache, I., Blasi, F., Welte, T., Haverich, A., Mainz, J. G., & Gottlieb, J. (2018) · Transplant Infectious Disease · doi:10.1111/tid.12924 · Cited by 32 · cited 1×
“263,264 264-267 Non-infectious comorbidities include malnutrition, which is common in CF patients approaching transplant and represents a potentially modifiable risk factor.”
BackgroundEvaluation of Risk Factors for Heart-Lung Transplant Recipient Outcome
Shudo, Y., Wang, H., Lingala, B., He, H., Kim, F. Y., Hiesinger, W., Lee, A. M., Boyd, J. H., Currie, M. E., & Woo, Y.-P. J. (2019) · Circulation · doi:10.1161/circulationaha.119.040682 · Cited by 32
Risk factors for disease progression in idiopathic pulmonary fibrosis
Raghu, G., Ley, B., Brown, K. M., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Noble, P. W., Song, J. W., Wells, A. U., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2019-213620 · Cited by 32
Survival and Extrapulmonary Course of Connective Tissue Disease After Lung Transplantation
Takagishi, T., Ostrowski, R., Alex, C., Rychlik, K., Pelletiere, K., & Tehrani, R. (2012) · JCR: Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e3182676089 · Cited by 31 · cited 11×
“The most familiar of these is the BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-minute walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation.”
BackgroundInfluentialLung transplantation in patients who have undergone prior cardiothoracic procedures
Omara, M., Okamoto, T., Arafat, A. A., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.05.030 · Cited by 31
McKellar, S. H., Bowen, M. E., Baird, B. C., Raman, S., Cahill, B. C., & Selzman, C. H. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.05.029 · Cited by 31 · cited 1×
“28 Considering the results of these studies, CAD should not be considered an absolute contraindication.”
BackgroundHow important is coronary artery disease when considering lung transplant candidates?
Koprivanac, M., Budev, M. M., Yun, J. J., Kelava, M., Pettersson, G. B., McCurry, K. R., Johnston, D. R., Mangi, A. A., Houghtaling, P. L., Blackstone, E. H., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.03.011 · Cited by 30 · cited 1×
“23-26 It is important to point out that these patients have been highly selected and more often undergo single lung transplant.”
BackgroundLung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma
Glanville, A. R., & Wilson, B. E. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30297-3 · Cited by 30 · cited 5×
“327 To exclude any extrapulmonary or lymphatic spread, staging with abdominal and chest CT, mediastinal lymph node sampling through endobronchial ultrasound-guided transbronchial needle aspiration or mediastinoscopy, brain MRI, and full-body PET should be performed prior to consideration of listing…”
BackgroundMethodInfluentialSelf-citationNeurological sequelae and clinical outcomes after lung transplantation
Smith, P. J., Stonerock, G. L., Ingle, K. K., Saulino, C. K., Hoffman, B., Wasserman, B., Blumenthal, J. A., Palmer, S. M., Klapper, J. A., Hartwig, M. G., et al. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000766 · Cited by 30
Self-citationRaats, D., Lorent, N., Saegeman, V., Vos, R., van Ingen, J., Verleden, G., Van Raemdonck, D., & Dupont, L. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13046 · Cited by 30
Seminars in Thoracic and Cardiovascular Surgery
(2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(14)00950-7 · Cited by 30
Outcomes following bronchial artery embolisation for haemoptysis in cystic fibrosis
Flight, W. G., Barry, P. J., Bright-Thomas, R. J., Butterfield, S., Ashleigh, R., & Jones, A. M. (2017) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-017-1626-0 · Cited by 28
Banga, A., Batchelor, E., Mohanka, M., Bollineni, S., Kaza, V., Mullins, J., Tran, M., Bajona, P., Peltz, M., Wait, M., et al. (2017) · Clinical Transplantation · doi:10.1111/ctr.12990 · Cited by 28 · cited 1×
“It is also a predictor of poor survival for lung transplant candidates while on the waiting list including those who require ECLS prior to lung transplant.(49,50) Functional Status and Frailty: Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is…”
BackgroundDaccò, V., Claut, L., Piconi, S., Castellazzi, L., Garbarino, F., Teri, A., & Colombo, C. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13082 · Cited by 28 · cited 1×
“74-77”
Salam, S., Kotloff, R., Garcha, P., Krishnan, S., Joshi, D., Grady, P., & Duggal, A. (2017) · ASAIO Journal · doi:10.1097/mat.0000000000000450 · Cited by 27
Self-citationFormer Smoking Is a Risk Factor for Chronic Kidney Disease After Lung Transplantation
Hellemons, M. E., Agarwal, P. K., van der Bij, W., Verschuuren, E. A. M., Postmus, D., Erasmus, M. E., Navis, G. J., & Bakker, S. J. L. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03701.x · Cited by 27
Solé, A., García-Robles, A. A., Jordá, C., Cases Viedma, E., Mancheño, N., Poveda-Andrés, J. L., Reig Mezquida, J. P., & Pemán, J. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14580 · Cited by 27 · cited 1×
“70,71 Burkholderia cepacia complex : Burkholderia cepacia complex includes several genotypically distinct bacteria, the most common of which are B. cenocepaci a and B.multi-vorans.”
BackgroundSelf-citationMayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis
Ussavarungsi, K., Hu, X., Scott, J. P., Erasmus, D. B., Mallea, J. M., Alvarez, F., Lee, A. S., Keller, C. A., Ryu, J. H., & Burger, C. D. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.08.014 · Cited by 26
Solé, A., Pérez, I., Vázquez, I., Pastor, A., Escrivá, J., Sales, G., Hervás, D., Glanville, A. R., & Quittner, A. L. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.1233 · Cited by 26
Self-citationCombined Lung-Kidney Transplantation: An Analysis of the UNOS/OPTN Database
Reich, H. J., Chan, J. L., Czer, L. S. C., Mirocha, J., Annamalai, A., Cheng, W., Jordan, S. C., Chaux, G. E., & Ramzy, D. (2015) · The American Surgeon · doi:10.1177/000313481508101027 · Cited by 26
Survival of Lung Transplant Candidates With COPD
Reed, R. M., Cabral, H., Dransfield, M. T., Eberlein, M. H., Merlo, C. A., Mulligan, M. J., Netzer, G., Sánchez, P. G., Scharf, S. M., Sin, D. D., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.10.008 · Cited by 26 · cited 1×
“169,170 Both found that the BODE index overestimated mortality.”
BackgroundSingle-center long-term analysis of combined liver-lung transplant outcomes
Freischlag, K. W., Messina, J., Ezekian, B., Mulvihill, M. S., Barbas, A., Berg, C., Sudan, D., Reynolds, J., Hartwig, M., & Knechtle, S. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000785 · Cited by 26 · cited 1×
“153,270 Finally, the risk of colorectal cancer is increased in CF compared to age-matched controls, and transplant programs should screen CF candidates with colonoscopy beginning at age 40 years based on the 2017 CF Foundation Guidelines.”
BackgroundSelf-citationPulmonary artery enlargement and mortality risk in moderate to severe COPD: results from COPDGene
LaFon, D. C., Bhatt, S. P., Labaki, W. W., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01812-2019 · Cited by 26
Kon, Z. N., Wehman, P. B., Gibber, M., Rabin, J., Evans, C. F., Rajagopal, K., Herr, D., Iacono, A., Garcia, J. P., & Griffith, B. P. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2014.04.097 · Cited by 25
Casswell, G. K., Pilcher, D. V., Martin, R. S., et al. (2013) · Pediatric Transplantation · doi:10.1111/petr.12152 · Cited by 25 · cited 1×
“Growth: In the pre-transplant period optimizing growth and nutritional status in children is important, not only as preparation for the operation, but also because growth may be attenuated by medications post-transplant Extracorporeal Membrane Oxygenation (ECMO): In the past, ECMO was considered a relative contraindic…”
BackgroundEl-Chemaly, S., Goldberg, H. J., & Glanville, A. R. (2014) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2014.956728 · Cited by 25
Self-citationOutcomes of Multi‐Organ Transplant in Adult Patients With Congenital Heart Disease
Wong, K. E., Tecson, K. M., & Cedars, A. M. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.014088 · Cited by 25
Epidemiology and Risk Factors for Cancer After Lung Transplantation
Berastegui, C., Laporta, R., López‐Meseguer, M., Laura, R. V., Gómez‐Ollés, S., Riera, J., Monforte, V., Sáez, B., Bravo, C., Román, A., et al. (2017) · Transplantation Proceedings · doi:10.1016/j.transproceed.2017.09.043 · Cited by 25 · cited 2×
“Transplant centers should work closely with oncology specialists to evaluate each patient with a history of cancer to determine the stagespecific risk of recurrence or progression, which may be higher in the setting of immunosuppression, and to determine the necessary cancer-free period prior to listing.(15,16) Renal…”
BackgroundA Comparison of frailty measures at listing to predict outcomes after lung transplantation
Halpern, A. L., Boshier, P. R., White, A. M., Houk, A. K., Helmkamp, L., Mitchell, J. D., Meguid, R. A., Low, D. E., Fullerton, D. A., & Weyant, M. J. (2020) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.07.040 · Cited by 25
Osho, A. A., Castleberry, A. W., Snyder, L. D., Ganapathi, A. M., Hirji, S. A., Stafford-Smith, M., Lin, S. S., Davis, R. D., & Hartwig, M. G. (2014) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2014.03.010 · Cited by 24
Self-citationNakajima, T., Cypel, M., de Perrot, M., Pierre, A., Waddell, T., Singer, L., Roberts, H., Keshavjee, S., & Yasufuku, K. (2015) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2015.02.006 · Cited by 24 · cited 1×
“324-326 Thus, lung transplant centers should establish protocols to screen candidates at higher risk for lung cancer.”
BackgroundSelf-citationGómez‐Román, J., Valle, C. E. D., Zarrabeitia, M. T., Martínez, J. M. C., Goñi, F. Z., Mons, R., Cuevas, J., & Val‐Bernal, J. F. (2005) · Pathology International · doi:10.1111/j.1440-1827.2005.01872.x · Cited by 24 · cited 1×
“323,331 In summary, the risk associated with lung transplant in candidates with thoracic malignancy is high, and each center therefore needs to consider whether the possible benefit outweighs this risk and balance the overall need for prioritization of transplantable organs.”
BackgroundCigarette Smoking Following Lung Transplantation
Bauldoff, G. S., Holloman, C. H., Carter, S., Pope‐Harman, A., & Nunley, D. R. (2014) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000096 · Cited by 24
Kishaba, T., McGill, R., Nei, Y., Ibuki, S., Momose, M., Nishiyama, K., Nagano, H., & Yamashiro, S. (2018) · The Journal of Medical Investigation · doi:10.2152/jmi.65.251 · Cited by 24
Conquering combined thoracic organ and liver transplantation
Yi, S. G., Lunsford, K. E., Bruce, C. R., et al. (2018) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000509 · Cited by 24
Los-Arcos, I., Len, O., Martín-Gómez, M. T., González-López, J. J., Saéz-Giménez, B., Deu, M., Nuvials, X., Ferrer, R., Román, A., & Gavaldà, J. (2019) · Infection · doi:10.1007/s15010-018-1261-y · Cited by 24
Arora, S. S., Axley, P., Ahmed, Z., Satapathy, S. K., Wong, R., Kuo, Y., & Singal, A. K. (2019) · Transplant International · doi:10.1111/tri.13424 · Cited by 24 · cited 1×
“Ideally, patients with HCV should be treated prior to lung transplant; however, patients with a detectable HCV viral load without significant liver fibrosis may be treated after lung transplant.(79,80) Human immunodeficiency virus (HIV): Case series have demonstrated comparable 1-year and 5-year survival for HIV-infec…”
BackgroundPredictive performance of different kidney function estimation equations in lung transplant patients
Degen, D. A., Janardan, J., Barraclough, K. A., Schneider, H. G., Barber, T., Barton, H., Snell, G., Levvey, B., & Walker, R. G. (2017) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2017.01.008 · Cited by 23
The Roles of Social Support and Psychological Distress in Lung Transplant Candidacy
Phillips, K. M., Burker, E. J., & White, H. (2011) · Progress in Transplantation · doi:10.7182/prtr.21.3.48q4vw7428q2786u · Cited by 23
The impact of waiting list BMI changes on the short-term outcomes of lung transplantation
Jomphe, V., Mailhot, G., Damphousse, V., Tahir, M.-R., Receveur, O., Poirier, C., & Ferraro, P. (2018) · Transplantation · doi:10.1097/tp.0000000000001919 · Cited by 23
Machuca, T. N., Losso, M. J., Camargo, S. M., Schio, S. M., Melo, I. A., Hochhegger, B., Felicetti, J. C., & Camargo, J. J. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2010.12.051 · Cited by 22
Pulmonary arterial enlargement predicts long-term survival in COPD patients
de-Torres, J. P., Ezponda, A., Alcaide, A. B., Campo, A., Bertó, J., González, J., Zulueta, J. J., Casanova, C., Rodriguez-Delgado, L. E., Celli, B. R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195640 · Cited by 22
Inci, I., Iskender, I., Ehrsam, J., Caviezel, C., Hillinger, S., Opitz, I., Schneiter, D., & Weder, W. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx318 · Cited by 22
The influence of retransplantation on survival for pediatric lung transplant recipients
Waseda, R., Benazzo, A., Höetzenecker, K., et al. (2018) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2018.05.080 · Cited by 22
Freischlag, K., Ezekian, B., Schroder, P. M., et al. (2018) · Transplantation · doi:10.1097/tp.0000000000002529 · Cited by 22 · cited 1×
“164 Lung-kidney transplant : A significant and increasing proportion of potential lung transplant candidates have established renal dysfunction.”
BackgroundSelf-citationOutcomes of endoscopic sinus surgery in adult lung transplant patients with cystic fibrosis
Luparello, P., Lazio, M. S., Voltolini, L., Borchi, B., Taccetti, G., & Maggiore, G. (2019) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-019-05308-9 · Cited by 22
Transitioning from pediatric to adult care after thoracic transplantation.
Putschoegl, A., Dipchand, A., Ross, H., Chaparro, C., & Johnson, J. N. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.02.023 · Cited by 21
Solid organ transplantation in HIV+ recipients: Italian experience
Morabito, V., Grossi, P., Lombardini, L., Ricci, A., Trapani, S., Peritore, D., Gaeta, A., Ballanti, D., Del Sordo, E., Rizzato, L., et al. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.12.049 · Cited by 21
Cantón‐Bulnes, M. L., Hurtado Martínez, Á., López‐Cerero, L., Arenzana Seisdedos, Á., Merino‐Bohorquez, V., & Garnacho‐Montero, J. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13034 · Cited by 21
Halloran, K., Hirji, A., Li, D., Jackson, K., Kapasi, A., Meyer, S., Mullen, J., Lien, D., & Weinkauf, J. (2019) · Transplantation · doi:10.1097/tp.0000000000002609 · Cited by 21 · cited 1×
“CAD was not associated with worse survival for patients undergoing percutaneous coronary intervention with stent placement prior to lung transplant or coronary artery bypass grafting (CABG) at the time of lung transplant.(23) In those patients with a history of prior”
Organ allocation and utilization in pediatric transplantation
Andrews, W. S., Kane, B. J., & Hendrickson, R. J. (2017) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2017.07.013 · Cited by 20
Khandhar, S. J., Althouse, A. D., Mulukutla, S., Kormos, R., Toma, C., Marroquin, O., Volz, E., Tefera, L., & Bermudez, C. (2017) · Clinical Transplantation · doi:10.1111/ctr.13026 · Cited by 20
Performance of the BODE index in patients with α1-antitrypsin deficiency-related COPD
Thabut, G., Mornex, J., Pison, C. M., Cuvelier, A., Balduyck, M., Pujazon, M.-C., Fournier, M., Aitilalne, B., & Porcher, R. (2014) · European Respiratory Journal · doi:10.1183/09031936.00168113 · Cited by 19
Lung transplantation with lungs from older donors: an analysis of survival in elderly recipients
Katsnelson, J., Whitson, B. A., Tumin, D., Ravi, Y., Kilic, A., Tobias, J. D., Sai-Sudhakar, C. B., & Hayes, D. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2017.02.059 · Cited by 19 · cited 1×
“One option to address this issue is the consideration of allocation of lungs from older donors to older recipients, as this has been demonstrated to result in comparable outcomes.(11,12) In summary, while older age is increasingly”
BackgroundExercise testing parameters associated with post lung transplant mortality
Armstrong, H. F., Garber, C. E., & Bartels, M. N. (2012) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2012.02.003 · Cited by 18 · cited 1×
“55,56 Pre-and post-transplant pulmonary rehabilitation should be recommended for transplant candidates and recipients.”
BackgroundHayes, D., Kopp, B. T., Tobias, J. D., Woodley, F. W., Mansour, H. M., Tumin, D., & Kirkby, S. E. (2015) · Lung · doi:10.1007/s00408-015-9811-x · Cited by 18
Transplantation for lung cancer
Machuca, T., & Keshavjee, S. H. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328357fff6 · Cited by 18 · cited 1×
“327,328 Considering the 6%-9% incidence of developing lung cancer in the native lung, bilateral lung transplant is preferred.”
BackgroundImaging biomarkers and staging in IPF
Walsh, S. L. F. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000507 · Cited by 18
Reassessing the BODE score as a criterion for listing COPD patients for lung transplantation
Pirard, L., & Marchand, É. (2018) · International Journal of COPD · doi:10.2147/copd.s182483 · Cited by 18 · cited 1×
“169,170 Both found that the BODE index overestimated mortality.”
BackgroundLung transplant patients with coronary artery disease rarely die of cardiac causes
Makey, I. A., Sui, J. W., Huynh, C., Das, N. A., Thomas, M., & Johnson, S. (2018) · Clinical Transplantation · doi:10.1111/ctr.13354 · Cited by 18 · cited 1×
“27 CAD was not associated with worse survival for patients undergoing percutaneous coronary intervention with stent placement prior to lung transplant or coronary artery bypass grafting (CABG) at the time of lung transplant.”
BackgroundOng, S., Levy, R. D., Yee, J., Partovi, N., Churg, A., Roméo, P., Chalaoui, J., Nador, R., Wright, A., Manganas, H., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0727-0 · Cited by 18
Patterns of recurrence and overall survival in incidental lung cancer in explanted lungs
Ahmad, U., Hakim, A. H., Tang, A., Tong, M. Z., Bribriesco, A., Budev, M., Mehta, A., Akindipe, O., Lane, C., McCurry, K. R., et al. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.09.022 · Cited by 18
Pretransplant Opioid Use and Survival After Lung Transplantation
Vahidy, S., Li, D., Hirji, A. S., Kapasi, A., Weinkauf, J. G., Laing, B., Lien, D. C., & Halloran, K. M. (2019) · Transplantation · doi:10.1097/tp.0000000000003050 · Cited by 18 · cited 1×
“121,122 The risk and benefit of opioids prescribed to lung transplant candidates to palliate symptoms of pain or dyspnea should be considered on an individual basis.”
BackgroundRecurrence of lymphangioleiomyomatosis: nine years after a bilateral lung transplantation
Zaki, K. S., Aryan, Z., Mehta, A. C., Akindipe, O., & Budev, M. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i1.249 · Cited by 17
Deaths Related to Bronchial Arterial Embolization in Patients With Cystic Fibrosis
Town, J. A., Monroe, E. J., & Aitken, M. L. (2016) · Chest · doi:10.1016/j.chest.2016.03.009 · Cited by 17
Hayes, D., Tumin, D., Budev, M. M., Tobias, J. D., St John, R. C., & Kukreja, J. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.04.010 · Cited by 17
Single lung transplantation for lymphangioleiomyomatosis: a single-center experience in Japan
Oishi, H., Watanabe, T., Matsuda, Y., Noda, M., Ejima, Y., Saiki, Y., Seyama, K., Kondo, T., & Okada, Y. (2018) · Surgery Today · doi:10.1007/s00595-018-1678-z · Cited by 17
Osho, A. A., Castleberry, A. W., Snyder, L. D., Palmer, S. M., Stafford-Smith, M., Lin, S. S., Duane Davis, R., & Hartwig, M. G. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.011 · Cited by 16
Self-citationPulmonary artery pressure and benefit of lung transplantation in adult cystic fibrosis patients
Hayes, D., Tumin, D., Daniels, C. J., McCoy, K. S., Mansour, H. M., Tobias, J. D., & Kirkby, S. E. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.09.086 · Cited by 16
Baldi, B. G., Samano, M. N., Campos, S. V., de Oliveira, M. R., Junior, J. E. A., Carraro, R. M., Teixeira, R. H. O. B., Minguini, I. P., Burlina, R., Pato, E. Z. S., et al. (2017) · Lung · doi:10.1007/s00408-017-0045-y · Cited by 16
Self-citationRatwani, A. P., Ahmad, K., Barnett, S. D., et al. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.05.020 · Cited by 16
Wille, K. M., Edwards, L. B., Callahan, L. R., McKoy, A. R., & Chan, K. M. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.03.001 · Cited by 15
Salman, J., Ius, F., Sommer, W., Siemeni, T., Fleissner, F., Alhadidi, H., Kugler, C., Avsar, M., Haverich, A., Warnecke, G., et al. (2019) · Progress in Transplantation · doi:10.1177/1526924819835815 · Cited by 15
Kurosaki, T., Otani, S., Miyoshi, K., Okazaki, M., Sugimoto, S., Suno, M., Yamane, M., Kobayashi, M., Oto, T., & Toyooka, S. (2020) · The Clinical Respiratory Journal · doi:10.1111/crj.13108 · Cited by 15
Characteristics and Outcomes of Lung Transplant Candidates With Preexisting Renal Dysfunction
Woll, F., Mohanka, M., Bollineni, S., Joerns, J., Kaza, V., Torres, F., Tanriover, B., & Banga, A. (2020) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.10.032 · Cited by 15 · cited 2×
“Active substance use or dependence including current tobacco use, vaping, marijuana smoking, or IV drug use 17.”
BackgroundÁlvarez-López, P., Riveiro-Barciela, M., Oleas-Vega, D., Flores-Cortes, C., Román, A., Perelló, M., Berastegui, C., Castells, L., Esteban, R., & Buti, M. (2020) · Medicine · doi:10.1097/md.0000000000019407 · Cited by 15
Influence of pulmonary hypertension on survival in advanced lung disease
Hayes, D., Black, S. M., Tobias, J. D., Mansour, H. M., & Whitson, B. A. (2015) · Lung · doi:10.1007/s00408-015-9696-8 · Cited by 14
Hayes, D., Kirkby, S., Whitson, B. A., Black, S. M., Sheikh, S. I., Tobias, J. D., Mansour, H. M., & Kopp, B. T. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.04.022 · Cited by 13
Successful lung re-transplant in a patient with cepacia syndrome due to Burkholderia ambifaria
Goodlet, K. J., Nailor, M. D., Omar, A., Huang, J. L., LiPuma, J. J., Walia, R., & Tokman, S. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.08.011 · Cited by 12 · cited 1×
“74-77”
Double lung transplantation in an HIV‐positive patient with Mycobacterium kansasii infection
Ambaraghassi, G., Ferraro, P., Poirier, C., Rouleau, D., & Fortin, C. (2019) · Transplant Infectious Disease · doi:10.1111/tid.12999 · Cited by 11
Nakagiri, T., Shintani, Y., Minami, M., Inoue, M., Funaki, S., Kawamura, T., & Okumura, M. (2015) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.04.103 · Cited by 10
Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis
Moua, T., Lee, A. S., & Ryu, J. H. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656069 · Cited by 10
Amano, M., Izumi, C., Baba, M., Abe, R., Matsutani, H., Inao, T., Miyake, M., Nishimoto, Y., Tamura, T., Noma, S., et al. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2019.08.010 · Cited by 10
Pediatric lung transplant: Correlation of pretransplant condition with post-transplant outcomes
Freiberger, D., Gould Delaney, A., Forbes, P., Manley, D., & Visner, G. A. (2021) · Pediatric Transplantation · doi:10.1111/petr.13889 · Cited by 10 · cited 1×
“55,56 Pre-and post-transplant pulmonary rehabilitation should be recommended for transplant candidates and recipients.”
BackgroundKomatsu, T., Oshima, A., Chen-Yoshikawa, T. F., Harashima, S.-I., Aoyama, A., Inagaki, N., & Date, H. (2017) · Surgery Today · doi:10.1007/s00595-017-1542-6 · Cited by 9 · cited 1×
“49,50 51-53 However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
BackgroundRevilla‐López, E., Berastegui, C., Sáez, B., López‐Meseguer, M., Monforte, V., Bravo, C., Sacanell, J., Laura, R. V., Moreno, A., & Román, A. (2019) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2018.12.018 · Cited by 9
Predictive Utility of Lung Allocation Score for Retransplantation Outcomes
Doyle, S., Hayes, D., Stewart, W. C. L., Whitson, B. A., Tobias, J. D., & Tumin, D. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.05.085 · Cited by 8 · cited 1×
“140,146,150,151 In the pre-transplant evaluation of such patients, particular emphasis should be focused on understanding the possible reasons for the graft failure, such as alloimmunization, poor adherence, GER, or repeated infections.”
BackgroundRevilla‐López, E., Berastegui, C., Sáez, B., López‐Meseguer, M., Monforte, V., Bravo, C., Sacanell, J., Laura, R. V., Moreno, A., & Román, A. (2018) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2018.07.025 · Cited by 8
Barrio, J., Sánchez, C., Vicente, R., Ramos, F., Montero, R., Morales, P., & Solé, A. (2004) · European Journal of Anaesthesiology · doi:10.1097/00003643-200404000-00017 · Cited by 8
Self-citationBarrio, J., Sánchez, C., Vicente, R., et al. (2004) · European Journal of Anaesthesiology · doi:10.1017/s0265021504264122 · Cited by 6
Self-citationCottin, V., Hansell, D. M., Sverzellati, N., et al. (2015) · doi:10.1183/13993003.congress-2015.oa4488 · Cited by 6 · cited 1×
“210,211 Predicting prognosis for individual patients with ILD remains difficult.”
BackgroundClinical outcomes of lung transplantation in patients with telomerase complex mutations
Tokman, S., Singer, J. P., Devine, M., Westall, G. P., Aubert, J., Tamm, M., Snell, G. I., Lee, J. S., Goldberg, H. J., Kukreja, J., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.01.376 · Cited by 4 · cited 2×
“38,39 40-42 In one study, when stratified by degree of obesity, the risk of mortality was increased for patients with a BMI > 35 and not in those with BMI 30-34.9.”
BackgroundInfluentialSelf-citationBlood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial
Maher, T. M., Jenkins, G. R., Cottin, V., et al. (2019) · doi:10.1183/13993003.congress-2019.oa1922 · Cited by 4
Distler, O., Highland, K. B., Gahlemann, M., et al. (2019) · doi:10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7360 · Cited by 3 · cited 1×
“198,199,201,202 Importantly, in two of these trials, patients were included on the basis of disease progression despite standard management.”
BackgroundRetrasplante pulmonar. Experiencia de un centro de referencia
Navarro, J. A. C., Peñafiel, S., Velandia, D. B., Ochoa, C. O., Pérez, S. T., Aragón, C. J., Bellorín, A. F., Niño, A. L., Jose Padilla, A., Aixelá, A. M., et al. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2020.02.008 · Cited by 1
Lung retransplant. Experience of a referral centre
Navarro, J. A. C., Peñafiel, S., Velandia, D. B., Ochoa, C. O., Pérez, S. T., Aragón, C. J., Bellorín, A. F., Niño, A. L., Jose Padilla, A., Aixelá, A. M., et al. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.02.009 · Cited by 1
FEV1 as a guide to lung transplant referral in young patients with cystic fibrosis
Robinson, W., & Waltz, D. A. (2000) · Pediatric Pulmonology · doi:10.1002/1099-0496(200009)30:3
Flagged first, then by citations
14 of the 363 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Wijsenbeek, M. S., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 576
Self-citationMaher, T. M. (2024) · JAMA · doi:10.1001/jama.2024.3669 · Cited by 435
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Bhakta, N. R., Bime, C., Kaminsky, D. A., McCormack, M. C., Thakur, N., Stanojevic, S., Baugh, A. D., Braun, L., Lovinsky‐Desir, S., Adamson, R., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202302-0310st · Cited by 316
“…is not used in the lung allocation score, the timing and listing for lung transplantation depends on — although it is not exclusively dependent on — FEV 1 (for COPD, cystic fi brosis, and lymphangioleiomyomatosis) and FVC (for interstitial lung disease) as a percentage of the predicted value (92).”
Progressive pulmonary fibrosis: an expert group consensus statement
Rajan, S. K., Cottin, V., Dhar, R., Danoff, S. K., Flaherty, K. R., Brown, K. K., Mohan, A., Renzoni, E. A., Mohan, M., V, Udwadia, Z., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.03187-2021 · Cited by 271
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
